Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Emerging targeted treatments for MDS

Norbert Vey • 5 May 2023
MDS 2023
Myelodysplastic Syndromes Antibodies

Norbert Vey, MD, PhD, Paoli-Calmettes Institute, Marseille, France, outlines some of the most promising targeted therapies in development for myelodysplastic syndromes (MDS), including drugs targeting IDH1/2 mutations, splicing factor gene mutations, and extracellular molecules. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Norbert Vey

0:55
The use of NGS to better risk stratify patients & identify druggable mutations in MDS
Norbert Vey • 5 May 2023
1:40
MDS 2023 highlights: classification and risk stratification systems & progression from CH to MDS
Norbert Vey • 5 May 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/HR-MDS: should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals